Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin ± all-trans retinoic acid ± granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome

Blood

Volumn 93, Issue 8, 1999, Pages 2478-2484

  Estey, Elihu H ^a   Thall, Peter F ^a   Pierce, Sherry ^a   Cortes, Jorge ^a   Beran, Miloslav ^a   Kantarjian, Hagop ^a   Keating, Michael J ^a   Andreeff, Michael ^a   Freireich, Emil ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; PROTEIN BCL 2; RETINOIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; APOPTOSIS; ARTICLE; BLOOD CELL COUNT; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CELL KILLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HIGH RISK POPULATION; HUMAN; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RECEPTOR DOWN REGULATION;

EID: 0033560841     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v93.8.2478.408k04_2478_2484     Document Type: Article

References (31)

1. Campos L, Rouault J-P, Sabido O, Oriol P, Roubi N, Vasselon C, Archimbaud E, Maguad JP, Guyotat D: High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 81:3091, 1993
2. Maung ZT, MacLean FR, Reid MM, Pearson ADJ, Proctor SJ, Hamilton PJ, Hall AG: The relationship between bcl-2 expression and response to chemotherapy in acute leukemia. Br J Haematol 88:105, 1994
3. 1 can confer a multidrug resistance phenotype. Blood 86:1903, 1995
4. Banker DE, Groudine M, Norwood T, Appelbaum FR: Measurement of spontaneous and therapeutic agent-induced apoptosis with bcl-2 protein expression in acute myeloid leukemia. Blood 89:243, 1997
5. Lishner M, Curtis JE, Minkin S, McCulloch EA: Interaction between retinoic acid and cytosine arabinoside affecting the blast cells of acute myeloblastic leukemia. Leukemia 3:784, 1989
6. Yang GS, Minden MD, McCulloch EA: Regulation by retinoic acid and hydrocortisone of the anthracycline sensitivity of blast cells of acute myeloblastic leukemia. Leukemia 8:2065, 1994
7. Hu Z-B, Minden MD, McCulloch EA: Direct evidence for the participation of bcl-2 in the regulation by retinoic acid of the ara-C sensitivity of leukemic stem cells. Leukemia 9:1667, 1995
8. Hu Z-B, Minden MD, McCulloch EA: Regulation of the synthesis of bcl-2 protein by growth factors. Leukemia 10:1925, 1996
9. Hu Z-B, Minden MD, McCulloch EA: Post-transcriptional regulation of bcl-2 in acute myeloblastic leukemia: Significance for response to chemotherapy. Leukemia 10:410, 1996
10. Fenaux P, Chastang C, Chomienne C, Castaigne S, Sanz M, Link H, Lowenberg B, Fey M, Archimbaud E, Degos L: Treatment of newly-diagnosed acute promyelocytic leukemia by all trans retinoic acid combined with chemotherapy: The European experience. Leuk Lymphoma 16:431, 1995
11. Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A, Shepherd L, Wilman C, Bloomfield CD, Rowe JM, Wiernik PH: All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 337:1021, 1997
12. Estey E, Thall P, Beran M, Kantarjian H, Pierce S, Keating M: Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia) on outcome of AML-type chemotherapy. Blood 90:2969, 1997
13. Tretinoin package insert. Hoffman-La Roche, Inc, 1995
14. Pocock SJ, Simon J: Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 31:103, 1975
15. Snedecor GW, Cochran WG: Statistical Methods, (ed 7). Ames, IA, Iowa State University Press, 1980
16. Fisher RA: The condition under which P2 measures the discrepancy between observation and hypothesis. J R Stat Soc 87:442, 1924
17. Mehta CR: The exact analysis of contingency tables in medical research. Stat Methods Med Res 3:135, 1994
18. Kaplan EL, Meier P: Nonparametric estimator from incomplete observations. J Am Stat Assoc 53:457, 1958
19. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 60:163, 1966
20. Cox DR: Regression models and life tables (with discussion). J R Stat Soc B 34:187, 1972
21. Fleming TR, Harrington DP: Counting Processes and Survival Analysis. New York, NY, Wiley, 1991
22. Grambsch PM, Therneau TM: Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 81:515, 1994
23. Cleveland WS: Robust locally-weighted regression and smoothing scatterplots. J Am Stat Assoc 74:829, 1979
24. Becker RA, Chambers JM, Wilks AR: The New S Language. Pacific Grove. CA, Wadsworth, 1988
25. Therneau TM: A package for survival analysis in S. Rochester, MN, Mayo Clinic Foundation, 1994
26. Ravandi-Kashani F, Hayes K, Lovshe D, Pierce S, Estey E: Prognostic significance of an unsuccessful cytogenetic analysis in newly-diagnosed AML. Blood 86:776a, 1995 (suppl 1, abstr)
27. Dombret H, Chastang C, Fenaux p, Reiffers J, Bordessoule D, Bouabdallah R, Mandelli F, Ferrant A, Auzanneau G, Tilly H, Yver A, Degos L: A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. N Engl J Med 332:1678, 1995
28. Heil G, Hoelzer D, Sanz MA, Lechner K, Yin JAL, Papa G, Noens L, Szer J, Ganser A, O'Brien C, Matcham J, Barge A: A randomized, double-blind, placebo controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. Blood 90:4710, 1997
29. Godwin JE, Kopecky KJ, Head DR, Willman CL, Leith CP, Hynes HE, Balcerzak SP, Appelbaum FR: A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: A Southwest Oncology Group Study (9031). Blood 91:3607, 1998
30. Estey E, Thall P, Andreeff M, Beran M, Kantarjian H, O'Brien S, Escudier S, Robertson LE, Koller C, Komblau S, Pierce S, Freireich E, Deisseroth A, Keating M: Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: Comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J Clin Oncol 12:671, 1994
31. Estey E, Beran M, Pierce S, Kantarjian H, Keating M: All-trans retinoic acid (ATRA) may improve results of chemotherapy in poor prognosis non-APL AML and MDS: A randomized study. Blood 90:416a, 1997 (suppl 1, abstr)